Previous 10 | Next 10 |
home / stock / mrna / mrna articles
A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement cas...
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for ...
On Tuesday, Cathie Wood’s Ark Invest made a significant move by increasing its stake in Moderna Inc. (NASDAQ:MRNA), a leading COVID-19 vaccin...
Ark Investment Management, led by Cathie Wood, continued to buy Tesla Inc. (NASDAQ:TSLA) shares on Monday, even though the stock had already r...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.27% on an annualized basis producing an average annual return of 40.2...
Money manager Cathie Wood’s Ark Invest has a favorite biotech holding now, going by the firm’s recent buying activity. What Happened: A...
On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CRYPTO: BTC) prices re...
Moderna Inc (NASDAQ:MRNA) shares are trading lower by 2.7% to $102.25 during Wednesday’s session in possible sympathy with BioNTech, which re...
On Monday, Cathie Wood-led Ark Invest made significant trades, notably offloading shares of Coinbase Global Inc (NASDAQ:COIN) and Block Inc (NYSE:S...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...